Login to Your Account

Other News To Note

Monday, February 28, 2011
Ipsen SA, of Paris, and BioMérieux SA, of Marcy l'Etoile, France, said they will collaborate to leverage Ipsen's portfolio of compounds and BioMérieux's diagnostic tests and identify programs that would benefit from the co-development of a therapeutic and a companion diagnostic test, notably in the prevention and treatment of prostate and breast cancers, neuro-endocrine tumors and pituitary tumors.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription